Menu
Search
|

Menu

Close
X

Lupin Ltd LUPN.NS (National Stock Exchange of India)

814.40 INR
-- (--)
As of 5:26 AM EST
chart
Previous Close 814.40
Open --
Volume --
3m Avg Volume 2,175,696
Today’s High --
Today’s Low --
52 Week High 1,498.00
52 Week Low 781.80
Shares Outstanding (mil) 452.06
Market Capitalization (mil) 372,992.59
Forward P/E 26.44
Dividend (Yield %) 7.50 ( 0.91 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.88 Mean rating from 42 analysts

KEY STATS

Revenue (mm, INR)
FY18
117,970
FY17
174,943
FY16
142,555
FY15
127,700
EPS (INR)
FY18
22.828
FY17
56.467
FY16
49.898
FY15
53.306
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
26.44
34.43
Price to Sales (TTM)
vs sector
2.32
8.57
Price to Book (MRQ)
vs sector
--
5.14
Price to Cash Flow (TTM)
vs sector
14.92
25.75
Total Debt to Equity (MRQ)
vs sector
--
15.12
LT Debt to Equity (MRQ)
vs sector
--
11.85
Return on Investment (TTM)
vs sector
--
13.54
Return on Equity (TTM)
vs sector
--
14.80

EXECUTIVE LEADERSHIP

Manju Gupta
Chairman of the Board, Since 2017
Salary: Rs4,570,000.00
Bonus: --
Vinita Gupta
Chief Executive Officer, Executive Director, Since 2013
Salary: Rs123,880,000.00
Bonus: --
Kamal Sharma
Executive Vice Chairman of the Board, Since 2013
Salary: Rs107,290,000.00
Bonus: --
Ramesh Swaminathan
Chief Financial Officer, Executive Director, Since 2015
Salary: Rs32,750,000.00
Bonus: --
Debabrata Chakravorty
President – Global Sourcing & Contract Manufacturing, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

B/4 Laxmi Towers
, Bandra Kurla Complex, Bandra (
MUMBAI     400051

Phone: +9122.66402222

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

SPONSORED STORIES